Please assess the completion status of the following clinical trial:

Trial Title: Role of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) on Inflammation and Lipids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* fasting plasma TG levels between 150 and 500 mg/dL~* C-reactive protein (CRP) levels ≥2 µg/mL~* at least one of the following criteria for the definition of metabolic syndrome:~  * abdominal obesity (waist circumference \>40 inches in men and \>35 inches in women),~ * hypertension (blood pressure ≥130/≥85 mmHg or use of anti-hypertensive medications), and~ * fasting glucose ≥110 mg/dL.~Exclusion criteria:~* high-fish diets (\>2 fish meals/week)~* taking fish oil supplements or supplements containing EPA or DHA~* allergy to sardines~* allergy to sunflower oil~* regular use of anti-inflammatory medications (NSAID, COX inhibitors, corticosteroids)~* anticoagulant therapy~* alcohol consumption \>7 drinks/week~* uncontrolled thyroid dysfunction~* insulin-dependent type 2 diabetes mellitus~* kidney or liver disease~* smoking~* alterations in coagulation~* use of lipid altering medications

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- EPA intervention (Type: EXPERIMENTAL): Subjects randomized to receive 3000 mg EPA/day, provided as EPA 750 mg/capsule will be instructed to take 2 capsules by mouth in the morning and 2 in the evening with meals for 10 weeks.
- DHA intervention (Type: EXPERIMENTAL): Subjects randomized to 3000 mg DHA/day provided as DHA 750 mg/capsule will instructed to take 2 capsules by mouth in the morning and 2 in the evening with meals for 10 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): 3000 mg high oleic acid sunflower oil/day; 750 mg high oleic acid sunflower oil/capsule; subjects instructed to take 2 capsules by mouth in the morning and 2 in the evening with meals during 4 week long lead-in phase.

Based on this trial design, predict the completion outcome and termination type (if applicable).